MAPK14 and plasma cell myeloma: Interestingly, p38 inhibition promotes differentiation and survival of monocyte-derived DC [10], and p38 inhibition or ERK activation restores deficiencies in DC function in myeloma patients [11], suggesting that treatment of DCs with pharmacological p38 inhibitors may be therapeutically useful.